NASDAQ$SLP

Simulations Plus Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Simulations Plus reported FY2020 and fourth quarter FY2020 financial results.

Simulations Plus reported an 18.9% increase in fourth quarter revenue, reaching $9.5 million. The company's diluted EPS for the quarter was $0.11.

  • Simulations Plus achieved its goal of accelerating organic growth to 15-20%.
  • Growth was driven by continued strong performance from both software and consulting revenue streams.
  • A strategic offering was completed, raising net proceeds of approximately $107.7 million to pursue additional acquisitions.
  • The company continues to generate solid profitability and free cash flow.

Headline financials

Total Revenue

$9.54M

Previous: $8.03M+18.9%
EPS (adj)

$0.11

Previous: $0.11+0.0%
Capital Expenditures

$126K

Previous: $61.9K+103.0%
Free Cash Flow

$4.68M

Previous: $4.06M+15.3%
Net Income

$2.19M

Previous: $2.06M+6.3%
Operating Income

$2.2M

Previous: $1.95M+13.0%
Gross Profit

$6.87M

Previous: $5.74M+19.7%
Cash & Equivalents

$49.2M

Previous: $11.4M+330.4%
Total Assets

$168M

Previous: $45.2M+272.6%
Stock-Based Comp

$432K

Previous: $302K+43.4%

Revenue & EPS history

Simulations Plus · Revenue · Quarterly

$9.54M

Q4 2020+18.9%vs Q4 2019
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Simulations Plus · $15.6M total across 2 segments · Q4 2023

  • Software
    $9.3M+57.6%
  • Services
    $6.3M+8.6%

Forward guidance

Simulations Plus achieved its goal of accelerating organic growth to 15-20%, overcoming headwinds from the COVID-19 pandemic due to continued strong growth from both our software and consulting revenue streams. Our future growth prospects were bolstered by a significant acquisition to expand our software business, growing our European presence, and the recent introductions of new software versions as well as the launch of several important collaborations. We continue to invest in R&D, funded both internally and from leading pharmaceutical and regulatory agencies, building on our leadership position in modelling and simulation for the drug development marketplace.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

+0.7%

Avg return

Earnings day

+1.1%

Avg return

5 days after

+4.7%

Avg return

30 days after

60%

39 / 65 earnings

Positive

+23.2%

Q2 2024

Best reaction

-24.2%

Q3 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026+3.9%+12.7%+28.4%
Q1 2026+8.5%+3.4%-28.1%
Q4 2025+14.2%+14.8%+6.5%
Q3 2025-0.5%+1.3%+9.8%
Q2 2025+7.8%+7.3%+39.9%
Q1 2025-3.1%-2.9%+22.3%
Q4 2024-9.6%-9.8%-8.6%
Q3 2024-13.6%-15.8%-13.4%
Q2 2024+23.2%+28.0%+21.0%
Q1 2024-8.2%-12.2%-15.3%
Q4 2023-16.2%-14.9%-0.4%
Q3 2023-3.5%+4.3%+16.3%
Q2 2023-0.3%+2.2%-3.7%
Q1 2023-6.1%-4.4%+14.7%
Q4 2022-12.7%-10.6%-11.1%
Q3 2022+8.5%+7.4%+31.1%
Q2 2022+6.9%+2.6%-10.4%
Q1 2022+4.7%+1.4%-14.8%
Q4 2021+16.9%+28.3%+29.6%
Q3 2021-17.4%-18.6%-13.2%
Q2 2021-2.5%+0.7%-12.5%
Q1 2021-13.6%-13.5%+0.2%
Q4 2020-8.4%-13.5%-11.5%
Q3 2020+1.0%+0.8%+6.5%
Q2 2020+4.4%+10.2%+16.8%
Q1 2020+9.1%+6.8%+11.5%
Q4 2019+3.7%+5.5%+0.1%
Q3 2019+10.4%+12.8%+34.4%
Q2 2019+11.8%+8.1%+17.4%
Q1 2019-7.1%-5.3%-4.5%
Q4 2018+0.3%-0.2%-6.0%
Q3 2018-24.2%-23.4%-22.5%
Q2 2018+9.8%+10.1%+24.5%
Q1 2018+1.9%+5.2%+1.3%
Q4 2017-4.5%-4.2%-2.1%
Q3 2017+5.8%+8.5%+8.5%
Q2 2017-2.2%+0.0%+9.4%
Q1 2017+4.2%+4.7%+1.6%
Q4 2016+2.9%+4.6%+10.9%
Q3 2016+0.5%+3.2%+5.4%
Q2 2016-0.8%
Q1 2016+1.5%
Q4 2015+4.6%
Q3 2015+12.6%
Q2 2015+0.7%
Q1 2015-0.9%
Q4 2014-2.0%
Q3 2014+5.7%
Q2 2014+1.0%
Q1 2014+6.3%
Q4 2013-6.1%
Q3 2013+2.8%
Q2 2013+1.0%
Q1 2013-1.6%
Q4 2012+0.9%
Q3 2012-0.7%
Q3 2011-0.7%
Q2 2012+1.1%
Q1 2012+2.0%
Q1 2011+2.0%
Q4 2011+2.0%
Q2 2011+2.0%
Q4 2010+3.1%
Q3 2010+0.8%
Q2 2009-0.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro